ClinicalTrials.gg
RecruitingNCT05689775Updated Jan 19, 2023

Reconstruction After Abdominoperineal Resection With Robot-assisted Harvest of VRAM Flap

An observational study in Perineum; Wound, Postoperative Complications and Rectal Neoplasms, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by Oslo University Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

Non-randomized study of robot-assisted perineal reconstruction with rectus abdominis muscle flap in patients operated with abdominoperineal resection for irradiated locally advanced rectal or anal cancer. Operative time, complications, wound healing, pre- and postoperatively abdominal wall strength and patient related outcomes including sexual health will be registered.

Read the detailed description

Inclusion criteria:

Patients > 18 years of age operated with robotic-assisted abdominoperineal resection for irradiated locally advanced rectal or anal cancer where robotic-assisted perineal and/or vaginal reconstruction has been performed with a rectus abdominis muscle flap.

Methods Up to 40 patients operated with robotic-assisted abdominoperineal resection with Da Vinci Xi surgical system (Intuitive Surgical, Sunnyvale, California, USA) and robotic-assisted reconstruction with a pedicled rectus muscle will be included in this prospective, non-randomized study.

In addition to the standardized post-operative care for patients with locally advanced rectal or anal cancer as specified by national guidelines, patients will be offered study-specific follow-up visits at 1, 6 and 12 months.

Complications are recorded by the accordion severity grading system of surgical complications. Patient related outcomes measures will be registered by using European organization for research and treatment of cancer Quality of life questionnaire Core 30 (EORTC QLQ-C30). Sexual health will be registered by a subset of questions from European organization for research and treatment of cancer Quality of life questionnaire Sexual health (EORTC QLQ-SH22).

Primary endpoint:

  • perineal wound healing at 3 months

Secondary endpoints:

  • early (\< 30 days) and late (> 30 days) complications
  • quality of life preoperatively and at 3- and 12 months postoperatively
  • sexual function preoperatively and at 3- and 12 months postoperatively
  • clinical evaluation of abdominal wall strength preoperatively, at 3- and 12 months postoperatively
02

Conditions studied

  • Perineum; Wound
  • Postoperative Complications
  • Rectal Neoplasms
  • Rectus Abdominis Hernia
  • Prospective Studies
  • Wound Heal
  • Sexual Health

Keywords

  • Rectus abdominis muscle flap
  • Reconstruction
  • Perineum
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 40 is below the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with rectal or anal cancer who are scheduled for robot-assisted abdominoperineal resection who need reconstruction of pelvic floor and/or vagina with rectus abdomens muscle flap.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with rectal or anal cancer
  • scheduled for robot-assisted abdominoperineal resection
  • reconstruction of pelvic floor and/or vagina with rectus abdominis muscle flap

Exclusion criteria

Exclusion Criteria:

  • patients not eligible for robot-assisted procedure
  • rectus abdominis muscle not available for harvest
  • the expected wound defect is not suitable for reconstruction with rectus abdominis muscle flap
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Patients

    Patients over 18 years of age operated for locally advanced anal or rectal cancer with robot-assisted abdomino-perinal resection and robot-assisted reconstruction of pelvic floor and/or vagina with vertical rectus abdomínis muscle flap.

    Procedure: Reconstruction with robot-assisted rectus abdominis muscle flap

Interventions

  • ProcedureReconstruction with robot-assisted rectus abdominis muscle flap

    Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.

06

What researchers measure

Primary outcomes

  1. Perineal wound healing

    Perineal wound healing at 3 months. Perineal wound has completely healed at clinical control 3 months postoperatively without need for further follow-up of the perineal wound. Any perineal complications are noted. * superficial wound infection * deep wound infection * minor wound dehiscence * major wound dehiscence * partial flap loss * total flap loss * perineal hernia * enterocutaneous fistula * stricture in neovagina * perineal wound dehiscence not related to flap * other complications

    Time frame: 3 months

Secondary outcomes

  1. Early postoperative complications

    Early postoperative complications at 30 days. A. Abdominal/donor-site complications * superficial wound infection * deep wound infection * minor wound dehiscence * major wound dehiscence * abdominal hernia * other complications B. Perineal complications * superficial wound infection * deep wound infection * minor wound dehiscence * major wound dehiscence * partial flap loss * total flap loss * perineal hernia * enterocutaneous fistula * stricture in neovagina * perineal wound dehiscence not related to flap * other complications C. Other complications * incisional hernia * parastomal hernia * reoperation * other complications Complications are classified as mild, moderate or severe according to Accordion severity grading system (Strasberg SM, Linehan DC, Hawkins WG. The Accordion severity grading system of surgical complications. Ann Surg 2009; 250: 177-86.)

    Time frame: Within 30 days postoperatively

  2. Late postoperative complications

    Late postoperative complications Perineal wound healing at 3 months. A. Abdominal/donor-site complications * superficial wound infection * deep wound infection * minor wound dehiscence * major wound dehiscence * abdominal hernia * other complications B. Perineal complications * superficial wound infection * deep wound infection * minor wound dehiscence * major wound dehiscence * partial flap loss * total flap loss * perineal hernia * enterocutaneous fistula * stricture in neovagina * perineal wound dehiscence not related to flap * other complications C. Other complications * incisional hernia * parastomal hernia * reoperation * other complications Complications are classified as mild, moderate or severe according to Accordion severity grading system (Strasberg SM, Linehan DC, Hawkins WG. The Accordion severity grading system of surgical complications. Ann Surg 2009; 250: 177-86.)

    Time frame: Later than 30 days postoperatively

  3. Quality of life - general

    Quality of life - EORTC-QLQ-C30

    Time frame: Preoperatively. 3 months and 12 months postoperatively.

  4. Quality of life - sexual

    Quality of life - EORTC-QLQ-SH22 - excerpt

    Time frame: Preoperatively. 3 months and 12 months postoperatively.

  5. Abdominal wall strength

    Clinical test of abdominal wall strength as described in (Nelson JA et al. Function and strength after free abdominally based breast reconstruction: A 10-year follow- up. Plastic and reconstructive surgery. 2019;143(1):22e-31e.

    Time frame: Preoperatively. 3 months and 12 months postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2024, 27 months after the start.

Of 265 non-industry observational studies under Wounds and Injuries, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 27 months is close to that.

Counting every sponsor, half of 312 studies reached it within 28 months; a quarter within 12 and three quarters within 60.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Jan 19, 2023
StartActual
Sep 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2026
Last update
Jan 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05689775
Responsible party
Lars Frich (Consultant, Oslo University Hospital) — Principal investigator
First posted
Jan 19, 2023
Start date
Sep 1, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 19, 2023

Study contacts

Lars Frich, MD, PhD
Contact
lfrich@ous-hf.no
004722930000
Lars Frich, MD, PhD
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion